Treatment of pityriasis rosea, a skin rash, with antiviral drug acyclovir

Treatment of pityriasis rosea with acyclovir - PRACT

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/09/002995

Enrollment

Registered

2012-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pityriasis rosea

Interventions

Intervention1: Acyclovir: 800 mg 5 times daily orally for 7 days. Control Intervention1: Placebo: Identical-looking placebo tablets 5 times daily orally for 7 days.

Eligibility

Inclusion criteria

Inclusion criteria: (a) Fulfillment of diagnostic criteria (Chuh 2003). (b) Informed consent given by the patient (c) Weight 40 kg or more

Exclusion criteria

Exclusion criteria: (a) Pregnancy (b) Lactation (c) Inability to come for weekly follow up visits (d) Any treatment in past one week (e) Any other illness as revealed by history (f) History of renal disease (g) History of drug reaction to acyclovir

Design outcomes

Primary

Measure	Time frame
Disappearance of skin lesions except post-inflammatory changes.Timepoint: Patients will be examined weekly.	—

Secondary

Measure	Time frame
50% reduction in severity.Timepoint: Patients will be examined weekly.	—

Countries

India

Contacts

Public ContactSanjay Singh

Institute of Medical Sciences, Banaras Hindu University

dranuragderma@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026